This company has been acquired
DICE Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
J. Judice
Chief executive officer
US$5.8m
Total compensation
| CEO salary percentage | 9.35% |
| CEO tenure | 10yrs |
| CEO ownership | 1.7% |
| Management average tenure | 2.6yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$104m |
| Mar 31 2023 | n/a | n/a | -US$91m |
| Dec 31 2022 | US$6m | US$540k | -US$84m |
| Sep 30 2022 | n/a | n/a | -US$77m |
| Jun 30 2022 | n/a | n/a | -US$74m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$6m | US$465k | -US$49m |
| Sep 30 2021 | n/a | n/a | -US$40m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$27m |
| Dec 31 2020 | US$637k | US$437k | -US$24m |
Compensation vs Market: J.'s total compensation ($USD5.77M) is about average for companies of similar size in the US market ($USD5.11M).
Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.
CEO
J. Judice (59 yo)
Dr. J. Kevin Judice, Ph D., founded DiCE Molecules SV, Inc. (formerly known as DiCE Molecules Corp). and serves as its Chief Executive Officer, President and Secretary. Dr. Judice has extensive experience...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10yrs | US$5.77m | 1.67% $ 38.0m | |
| Chief Business & Financial Officer | 5.7yrs | US$2.67m | 0.41% $ 9.4m | |
| Chief Medical Officer | 3yrs | US$2.72m | 0.32% $ 7.2m | |
| Chief Scientific Officer | 2.2yrs | US$714.79k | 0.31% $ 7.0m | |
| General Counsel | 1.4yrs | no data | no data | |
| Senior Vice President of CMC | 2.2yrs | no data | no data | |
| Senior Vice President of Medicinal Chemistry | no data | no data | no data |
Experienced Management: DICE's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | US$5.77m | 1.67% $ 38.0m | |
| Independent Director | 2.8yrs | US$264.90k | 0.10% $ 2.4m | |
| Independent Chairman of the Board | 7.7yrs | US$371.88k | 0.018% $ 400.6k | |
| Independent Director | 2.8yrs | US$264.90k | 0.086% $ 1.9m | |
| Independent Director | 1.4yrs | US$552.51k | 0% $ 0 | |
| Independent Director | 2.7yrs | US$231.45k | no data | |
| Independent Director | 1.4yrs | US$552.51k | 0% $ 0 |
Experienced Board: DICE's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/10 17:35 |
| End of Day Share Price | 2023/08/08 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DICE Therapeutics, Inc. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |